Christophe Lahorte

Christophe Lahorte

Christophe Lahorte

Head of National Innovation Office & Scientific-Technical Advice Unit - Federal Agency for Medicines and Healthcare Products (FAMHP)

Christophe Lahorte, PhD. is a pharmacist by training and has performed academic research for 6 years at the University of Ghent related to the chemical-pharmaceutical, non-clinical and clinical development of new radiopharmaceuticals for diagnostic and therapeutic use.


Since September 2004 he has been actively involved within the R&D department of the Belgian  agency for medicines and health products (FAMHP) in the quality assessment of clinical trial applications (CTA’s) and paediatric investigation plans (PIP’s). Since end 2007 he was member of the Paediatric Committee formulation working group (PDCO FWG) of the European Medicines Agency (EMA) for 3.5 years.


As a quality assessor he was also involved in the assessment of national and European scientific advice requests and assisted in several GMP inspections related to radiopharmaceuticals. Since april 2009 has been the head of the FAMHP’s Sientific-Technical/Regulatory Advice & Knowledge Management Unit. As of May 2017 he is also the head of the national Innovation Office at the FAMHP. The Innovation Office is especially focussed on the acceleration and facilitation of innovative medicines and health care products developed by eg. academic research laboratories (universities, research organisations, start-ups) and SME’s as well as large companies. As the head of the Innovation Office, he is the FAMHP´s representative at the EU-Innovation Network (EU-IN) and at the “Medicines and device borderline and combination products co-ordination working group” coordinated by the Heads of Medicines Agencies (HMA) and the EMA. He has gained considerable experience in the field of scientific and technical/regulatory advice, including aspects specifically related to early phase drug development. He has also participated in national and European research projects and educational projects and collaborated with several International Institutions such as the European Institute for Transuranium Elements (ITU, Karlsruhe, Germany) and the International Atomic Energy Agency (IAEA, Vienna, Austria).


Christophe Lahorte will present a lecture in the TEST session of the programme, together with Nathalie Lambot.


"Clinical Trials in Belgium: How innovation will drive the future?"

Belgium constitutes an unique health ecosystem in which clinical research can thrive. Thanks to a shared vision and common focus on solutions between the regulators, the industry, the researchers and the government, Belgium has been able to put itself on the map as one of the preferred locations for conducting trials in Europe (and even around the world). As a result, Belgium is systematically among the three countries in the clinical trials applications per millions inhabitants in the EU., the Belgian association of the innovative (bio)pharmaceutical industry will present the results of its annual analysis of the Belgian footprint of clinical trials conducted with Deloitte. This analysis puts the Belgian landscape in an European perspective, and highlights the strengths of the country, which explain its competitive position about clinical trials, as well as the challenges and the opportunities for the country.

The Federal Agency for Medicines and Health Products (FAMHP) who is the Belgian competent authority in charge of the evaluation and approval of clinical trials conducted in Belgium will present an overview of the key activities and ongoing projects of it’s Innovation Office at national and EU level. The key mission of the FAMHP’s Innovation Office is to facilitate the translation of innovative scientific advances into new medicines and healthcare products meeting adequate standards and by doing so to accelerate patients’ access to promising new therapies and to contribute to the vibrant Belgian health ecosystem. Strategic Partners Supporting Partners